
The FDA is poised to render a decision on Moderna's mRNA-based flu shot, which could be the first of its kind to market. The decision is expected to reverberate throughout the biotech industry.
(Image credit: Maddie Meyer)
Continue reading
Read the full report at NPR News
NPR News supplies a brief version of this story through its feed. Continue to the original publication for the complete report.
Read the original at NPR News

